...
首页> 外文期刊>Investigative ophthalmology & visual science >Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma.
【24h】

Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma.

机译:替莫洛尔-多佐胺固定组合和拉坦前列素对青光眼昼夜舒张压眼灌注压的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the effect of the timolol-dorzolamide fixed combination (TDFC) and latanoprost 0.005% on 24-hour intraocular pressure (IOP), systolic (SBP) and diastolic (DBP) blood pressure, and diastolic ocular perfusion pressure (DOPP) in patients with primary open-angle glaucoma (POAG). METHODS: This was an institutional, randomized clinical trial. After a 24-hour assessment without treatment, 27 previously untreated patients with POAG were randomized to 6 weeks' treatment with twice-daily TDFC (8 AM and 8 PM) followed by once-daily latanoprost 0.005% (8 PM), or vice versa. One eye was analyzed per patient. The mean values of IOP, DBP, SBP, and DOPP (difference between DBP and IOP) were recorded at each time point, and the 24-hour data are the mean values of each patient's measurements over the 24-hour period. The differences between the values of the first treatment period and the baseline and the second treatment period and washout were calculated and analyzed by means of an analysis of variance model that tested the effects of sequence and treatment. RESULTS: Both treatments significantly reduced 24-hour IOP (P < 0.0001), but TDFC led to lower 24-hour pressure (mean +/- SD: 15.4 +/- 1.9 vs. 16.7 +/- 1.7 mm Hg; P = 0.004). Latanoprost did not lead to any significant reduction in mean 24-hour SBP and DBP (SBP: P = 0.952; DBP: P = 0.831), but TDFC did (SBP and DBP: P < 0.0001). Both treatments significantly increased 24-hour DOPP (P < 0.0001), with no difference between the two medications (P = 0.09). CONCLUSIONS: In previously untreated patients with POAG, TDFC, and latanoprost equally enhanced 24-hour DOPP: the former by counteracting the decrease in DBP with a substantial reduction in IOP and the latter by not affecting DBP and significantly reducing IOP. (isrctn.org number, ISRCTN67123277.).
机译:目的:评估替莫洛尔-多唑胺固定组合(TDFC)和拉坦前列素0.005%对24小时眼内压(IOP),收缩压(SBP)和舒张压(DBP)以及舒张压眼灌注压(DOPP)的影响原发性开角型青光眼(POAG)的患者。方法:这是一项随机的临床试验。经过24小时不治疗的评估后,将27例先前未接受过治疗的POAG患者随机分为6周,分别每日两次TDFC(上午8点和下午8点),然后每天一次使用拉坦前列素0.005%(下午8点),反之亦然。每位患者分析一只眼睛。在每个时间点记录IOP,DBP,SBP和DOPP的平均值(DBP和IOP之间的差异),而24小时数据是每位患者在24小时内测量的平均值。通过方差分析模型来计算和分析第一治疗期和基线的值之间的差异,以及第二治疗期和洗脱的值之间的差异,该模型测试了序列和治疗的效果。结果:两种疗法均显着降低24小时IOP(P <0.0001),但TDFC导致24小时压力降低(平均+/- SD:15.4 +/- 1.9与16.7 +/- 1.7 mm Hg; P = 0.004 )。 Latanoprost不会导致平均24小时SBP和DBP显着降低(SBP:P = 0.952; DBP:P = 0.831),但TDFC却导致(SBP和DBP:P <0.0001)。两种治疗均显着增加24小时DOPP(P <0.0001),两种药物之间无差异(P = 0.09)。结论:在先前未接受过治疗的POAG,TDFC和拉坦前列素患者中,24小时DOPP均得到同样的增强:前者通过抵消DBP的降低而使IOP大幅降低,而后者则通过不影响DBP并显着降低IOP来提高。 (isrctn.org编号,ISRCTN67123277。)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号